Diversifying and Mitigating Development Risk Through Multiple Candidate Compounds
First written in FY2016. 25 of 30 entries say "Restated". Latest entry: FY2026.
The whole theme swung hardest in 2024: 2 of 6 companies on the "Worse" side.
2 other companies' latest entry also says "Restated".
- FY2026RestatedAnnual report
「The Company maintains multiple mutually independent candidate compounds in its development pipeline and backup compounds for each of them, thereby seeking to minimize losses in conducting its business if any obstacle arises during the development process.」
The company continues to diversify development risk through multiple independent candidate compounds and backup compounds. - 2026-08-12RestatedManagement Planning
「CBT005 (preparing for preclinical studies) CBS9106 (Phase 1 completed) CBP-A08 and others」
The Company maintained multiple follow-on pipelines, categorizing CBT005 as being in preparation for preclinical studies and CBS9106 as having completed Phase 1. - FY2026-H1RestatedAnnual report
「The clinical-stage drug candidate compounds currently under development are at the stage of preparing a Phase 3 clinical trial for CBP501 in pancreatic cancer, while CBS9106 has completed its Phase 1 clinical trial and is at the stage of considering its future development strategy.」
The Company continues to maintain a pipeline comprising multiple candidate compounds, namely CBP501 and CBS9106. - FY2025-H1RestatedAnnual report
「In addition to advancing the development of these 2 candidate compounds, we are conducting exploratory research and development preparations to generate new candidate compounds and expand our development pipeline, including CBT005 and CBP-A08, which were created based on new insights obtained during their development, and IDO/TDO inhibitors being optimized through joint research with Shizuoka University of Art and Science.」
The Company continues initiatives to expand its follow-on pipeline while developing multiple candidate compounds, including CBP501 and CBS9106. - FY2024-Q3RestatedAnnual report
「In addition to advancing the development of these 2 candidate compounds, we are conducting exploratory research to generate new candidate compounds and expand our development pipeline, including CBT005 and CBP-A08, which were created based on new insights obtained during their development, and IDO/TDO inhibitors being optimized through joint research with Shizuoka University of Art and Science.」
The Company continues its policy of advancing development of multiple clinical candidate compounds while expanding its follow-on pipeline, including CBT005, CBP-A08 and IDO/TDO inhibitors, in parallel. - FY2024-Q2AdvancedAnnual report
「We are conducting exploratory research to generate new candidate compounds and expand our development pipeline, including CBT005 and CBP-A08, which were created based on new insights obtained during their development, and IDO/TDO inhibitors being optimized through joint research with Shizuoka University of Art and Science. Among these compounds, we decided to advance CBT005 to preclinical trials, an early stage of development involving nonclinical studies required to compile the data needed for an application to commence clinical trials, and began preparations for them.」
With respect to expanding the development pipeline through multiple candidate compounds, the Company has reached the specific stage of advancing CBT005 to preclinical trials. - FY2024-Q1RestatedAnnual report
「In addition to advancing the development of these 2 candidate compounds, we are conducting exploratory research to generate new candidate compounds and expand our development pipeline, including CBT005 and CBP-A08, which were created based on new insights obtained during their development, and IDO/TDO inhibitors being optimized through joint research with Shizuoka University of Art and Science.」
The Company continues its policy of advancing development of multiple clinical candidate compounds while expanding its follow-on pipeline in parallel. - FY2023RestatedAnnual report
「The Company maintains multiple mutually independent candidate compounds in its development pipeline and backup compounds for each of them, thereby seeking to minimize losses in conducting its business if any obstacle arises during the development process.」
The Company continues initiatives to diversify development risk by maintaining multiple independent candidate compounds and backup compounds. - FY2023-Q3RestatedAnnual report
「In addition to advancing the development of these 2 candidate compounds, we are conducting exploratory research to generate new candidate compounds and expand our development pipeline, including CBT005 and CBP-A08, which were created based on new insights obtained during their development, and IDO/TDO inhibitors being optimized through joint research with Shizuoka University of Art and Science.」
The Company continues to develop CBP501 and CBS9106 and expand its follow-on pipeline, including CBT005, CBP-A08 and IDO/TDO inhibitors. - FY2022RestatedAnnual report
「The Company maintains multiple mutually independent candidate compounds in its development pipeline and backup compounds for each of them, thereby seeking to minimize losses in conducting its business if any obstacle arises during the development process.」
The Company continues initiatives to diversify development risk by maintaining multiple independent candidate compounds and backup compounds. - FY2022-Q3RestatedAnnual report
「There is no guarantee that development of these candidate compounds will progress smoothly, that they will be approved as drugs, or that they will contribute to business revenue in the future. Moreover, if development progresses smoothly, substantial additional funds will be required to continue development, making partnerships with pharmaceutical companies or others necessary as a source of such funds. At present, the Company has no partnership with a pharmaceutical company or other entity for CBP501. Although it has a partnership for CBS9106, no revenue is currently being generated from that partnership.」
The Company continues to maintain a structure in which it advances development of CBP501 and CBS9106 while exploring follow-on candidate compounds and expanding its development pipeline. - FY2022-Q2AdvancedAnnual report
「In addition to advancing the development of these 2 candidate compounds, we are conducting exploratory research to generate new candidate compounds and expand our development pipeline, including CBT005 and CBP-A08, which were created based on new insights obtained during their development, and IDO/TDO inhibitors being optimized through joint research with Shizuoka University of Art and Science.」
The Company has specifically indicated the expansion of its follow-on pipeline, including CBT005, CBP-A08 and IDO/TDO inhibitors, in addition to development of CBP501 and CBS9106. - FY2021RestatedAnnual report
「The Company maintains multiple mutually independent candidate compounds in its development pipeline and backup compounds for each of them, thereby seeking to minimize losses in conducting its business if any obstacle arises during the development process.」
The Company continues initiatives to diversify development risk through multiple independent candidate compounds and backup compounds. - FY2021-Q3RestatedAnnual report
「In addition to advancing the development of these 2 candidate compounds, we are conducting exploratory research to generate new candidate compounds and expand our development pipeline, including CBP-A08, which was created based on new insights obtained during their development, and IDO/TDO inhibitors being optimized through joint research with Shizuoka University of Art and Science.」
The Company continues to develop multiple clinical candidate compounds and expand its follow-on pipeline, including CBP-A08 and IDO/TDO inhibitors. - FY2021-Q2RestatedAnnual report
「In addition to advancing the development of these 2 candidate compounds, we are conducting exploratory research to generate new candidate compounds and expand our development pipeline, including CBP-A08, which was created based on new insights obtained during their development, and IDO/TDO inhibitors being optimized through joint research with Shizuoka University of Art and Science.」
The Company continues initiatives to expand its follow-on pipeline, including CBP-A08 and IDO/TDO inhibitors, while developing multiple clinical candidate compounds. - FY2021-Q1RestatedAnnual report
「In addition to advancing the development of these 2 candidate compounds, we are conducting exploratory research to generate new candidate compounds and expand our development pipeline, including CBP-A08, which was created based on new insights obtained during their development, and IDO/TDO inhibitors being optimized through joint research with Shizuoka University of Art and Science.」
The Company continues initiatives to expand its follow-on pipeline, including CBP-A08 and IDO/TDO inhibitors, while developing multiple clinical candidate compounds. - FY2020RestatedAnnual report
「The Company maintains multiple mutually independent candidate compounds in its development pipeline and backup compounds for each of them, thereby seeking to minimize losses in conducting its business if any obstacle arises during the development process.」
The Company continues initiatives to diversify development risk through multiple independent candidate compounds and backup compounds. - FY2020-Q3RestatedAnnual report
「In addition to advancing the development of these 2 candidate compounds, we are conducting exploratory research using our proprietary drug screening method to generate new candidate compounds, including CBP-A08, which was created based on new insights obtained during their development, and expand our development pipeline.」
The Company continues initiatives to create new candidate compounds and expand its development pipeline while advancing development of multiple candidate compounds. - FY2020-Q2RestatedAnnual report
「In addition to advancing the development of these 2 candidate compounds, we are conducting exploratory research using our proprietary drug screening method to generate new candidate compounds, including CBP-A08, which was created based on new insights obtained during their development, and expand our development pipeline.」
The Company continues initiatives to create new candidate compounds and expand its development pipeline while developing multiple candidate compounds. - FY2020-Q1RestatedAnnual report
「In addition to advancing the development of these 2 candidate compounds, we are conducting exploratory research using our proprietary drug screening method to generate new candidate compounds, including CBP-A08, which was created based on new insights obtained during their development, and expand our development pipeline.」
The Company continues initiatives to expand its development pipeline by creating new candidate compounds while developing multiple candidate compounds. - FY2019-Q3RestatedAnnual report
「In addition to advancing the development of these 2 candidate compounds, we are conducting exploratory research using our proprietary drug screening method to generate new candidate compounds, including CBP-A08, and expand our development pipeline.」
While advancing development of the two candidate compounds, CBP501 and CBS9106, the Company continues to expand its development pipeline by adding new candidate compounds such as CBP-A08. - FY2019-Q2RestatedAnnual report
「In addition to advancing the development of these 2 candidate compounds, we are conducting exploratory research using our proprietary drug screening method to generate new candidate compounds, including CBP-A08, and expand our development pipeline.」
While advancing development of the two candidate compounds, CBP501 and CBS9106, the Company continues to expand its development pipeline by adding new candidate compounds such as CBP-A08. - FY2019-Q1RestatedAnnual report
「The drug candidate compounds currently under development are at the stage of conducting a Phase 1b clinical trial for CBP501 based on new findings following completion of the Phase 2 clinical trial, and at the Phase 1 clinical trial stage for CBS9106.」
The Company continues to maintain a development portfolio comprising multiple candidate compounds, including CBP501 and CBS9106. - FY2018-Q3RestatedAnnual report
「In addition to advancing the development of these 2 candidate compounds, we are conducting exploratory research using our proprietary drug screening method to generate new candidate compounds and expand our development pipeline.」
While advancing development of CBP501 and CBS9106, the Company continues to create new candidate compounds through proprietary screening and expand its development pipeline. - FY2018-Q2RestatedAnnual report
「In addition, during the cumulative second-quarter period, with a view to enhancing corporate value over the medium to long term, we focused on optimizing new candidate compound groups following CBP501 and CBS9106. As a result, we acquired the new candidate compound CBP-A08. Taking financial constraints and other factors into account, we will prepare for CBP-A08 to enter preclinical trials in the near future.」
The acquisition of CBP-A08 and preparations for preclinical trials have been reaffirmed as concrete progress in the new candidate compound groups following the previous quarter. - FY2018-Q1AdvancedAnnual report
「In addition, during the cumulative first-quarter period, with a view to enhancing corporate value over the medium to long term, we focused on optimizing new candidate compound groups following CBP501 and CBS9106. As a result, we acquired the new candidate compound CBP-A08.」
The Company specifically acquired CBP-A08 through the optimization of candidate compound groups following CBP501 and CBS9106, thereby expanding its development portfolio. - FY2017AdvancedAnnual report
「The Company is currently building its development pipeline around CBP501, CBS9106 and next-generation compound groups, and is advancing research and development based on prioritization and management with commercialization in mind.」
The pipeline was expanded to explicitly include next-generation compound groups in addition to the two existing candidate compounds. - FY2017-Q3RestatedAnnual report
「The drug candidate compounds currently under development are at the stage of having completed the Phase 2 clinical trial for CBP501 and being in the Phase 1 clinical trial for CBS9106.」
The Company continues to maintain a development portfolio centered on the two candidate compounds, CBP501 and CBS9106. - FY2017-Q1RestatedAnnual report
「The drug candidate compounds currently under development are at the stage of having completed the Phase 2 clinical trial for CBP501 and being in the Phase 1 clinical trial for CBS9106.」
The Company continues to maintain a development portfolio centered on the two candidate compounds, CBP501 and CBS9106. - FY2016First statedAnnual report
「We have 2 independent candidate compounds, CBP501 and CBS9106, in our development pipeline and hold backup compounds for each, thereby seeking to minimize business losses if any obstacles arise during development.」
The company seeks to reduce its dependence on any single compound by maintaining 2 independent candidate compounds and backup compounds.